133492-69-0 Usage
General Description
Benzenemethanamine, 2,4-dichloro-a-methyl-, (S)- is a chemical compound with stereochemistry, S, and a molecular formula of C8H10Cl2N. It is a derivative of methamphetamine and is commonly known as l-methamphetamine. Benzenemethanamine,2,4-dichloro-a-methyl-,(S)- is a central nervous system stimulant and is classified as a Schedule II controlled substance due to its potential for abuse and addiction. It has a high potential for abuse and is often found in illicit drug formulations. Benzenemethanamine,2,4-dichloro-a-methyl-,(S)- acts on the neurotransmitters in the brain, increasing levels of dopamine and norepinephrine, resulting in a heightened sense of alertness and euphoria. It is often used in the illegal manufacture of methamphetamine and poses serious health risks, including addiction, overdose, and neurological damage, when abused.
Check Digit Verification of cas no
The CAS Registry Mumber 133492-69-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,4,9 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 133492-69:
(8*1)+(7*3)+(6*3)+(5*4)+(4*9)+(3*2)+(2*6)+(1*9)=130
130 % 10 = 0
So 133492-69-0 is a valid CAS Registry Number.
133492-69-0Relevant articles and documents
COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS
-
Page/Page column 45-49; 62, (2010/12/31)
The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.
Quinoxaline compounds
-
Page/Page column 17, (2008/06/13)
Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.